This HTML5 document contains 197 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1182/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34008578
rdf:type
wikibase:Item
schema:description
2012年の論文 научная статья мақолаи илмӣ articol științific tudományos cikk article scientifique (publié 2012) 2012年学术文章 artikulong pang-agham vedecký článok videnskabelig artikel (udgivet 2012) artículo científico publicado en 2012 2012年學術文章 artigo científico (publicado na 2012) artículu científicu espublizáu en 2012 мақолаи илмӣ vitskapeleg artikkel vetenskaplig artikel 2012年学术文章 2012年學術文章 artykuł naukowy wissenschaftlicher Artikel vitenskapelig artikkel article científic 2012年學術文章 2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված artigo científico teaduslik artikkel mokslinis straipsnis مقالة علمية نشرت بتاريخ 14-12-2012 vědecký článek 2012年学术文章 2012 nî lūn-bûn 2012年学术文章 научна статия artigo científico (publicado na 2012) wetenschappelijk artikel наукова стаття, опублікована в грудні 2012 مقالهٔ علمی სამეცნიერო სტატია bài báo khoa học bilimsel makale 2012年学术文章 บทความทางวิทยาศาสตร์ 2012年學術文章 artikull shkencor scienca artikolo ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ scientific article 2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած 2012年學術文章 naučni članak سائنسی مضمون 2012년 논문 מאמר מדעי article scientific научни чланак tieteellinen artikkeli научни чланак 2012年學術文章 επιστημονικό άρθρο articolo scientifico
p:P577
wds:Q34008578-5EBA7D05-B677-43F5-AA30-A6B53226A8DB
wdt:P577
2012-12-14T00:00:00Z
p:P407
wds:Q34008578-513D89E1-E84C-4D34-A06E-91AEF593AC05
wdt:P407
wd:Q1860
p:P2860
wds:Q34008578-46091D31-4749-446E-9683-C5A2BF49769B wds:Q34008578-39C37104-AF47-4993-A503-56E8674F245D wds:Q34008578-63A63B09-8E14-417F-B9D8-FAD9F1F2D322 wds:Q34008578-66C62463-3775-4BBF-80A0-68B391204101 wds:Q34008578-4FC2E4AC-8FBF-4095-867F-99173152DB64 wds:Q34008578-52100530-148F-4EFC-973A-45CFDAFBC948 wds:Q34008578-5C012A6D-BAD3-4B22-B90B-D0EEF7FBDF9B wds:Q34008578-6F692B53-6A28-4412-AF5E-9A360D3056B7 wds:Q34008578-9259B79A-8C2A-4713-BC55-A40C4DD35340 wds:Q34008578-9BEA0E60-9652-456C-B34A-FA1B496BA6F9 wds:Q34008578-09D459DD-55E4-4916-B7FF-B4CEEFF59637 wds:Q34008578-0AD3C557-29CE-4199-9D8D-C4DFCC19E755 wds:Q34008578-1CAE8FC5-50DA-4BE5-965B-B11F6F2A28C1 wds:Q34008578-1DD43936-49EA-4D42-AB23-EB57A04ECEAB wds:Q34008578-B1C319D6-1CEC-4AEF-BDF0-ADAEA0860A15 wds:Q34008578-C5F8251A-6BF4-4049-A4C6-70DEE43A6C9F wds:Q34008578-C64314BA-3583-4EF9-A32F-3C3D2DE0A96C wds:Q34008578-A9BFF5B7-5472-43CB-8DC0-F32755F2C35C wds:Q34008578-AC61308F-5674-42B1-85AB-1C09A2680D5A wds:Q34008578-B0D90047-BA32-4F06-831E-BE04A746381A wds:Q34008578-B1670AAA-E47F-4641-8861-2671C8D86795 wds:Q34008578-ED223BD7-AC3F-49E0-90DF-610E2C13BD2D wds:Q34008578-D34C05CD-8DE8-4FB5-AAC7-F7073E7D98B3 wds:Q34008578-D5BFB0E0-D715-44E3-A0CD-D361E7DC3095 wds:Q34008578-FC4A2D47-F6D9-4C03-BE80-77A537E637DA
wdt:P2860
wd:Q33322921 wd:Q36865500 wd:Q44971172 wd:Q40181640 wd:Q54032425 wd:Q39801960 wd:Q33348702 wd:Q44975171 wd:Q35848744 wd:Q35794132 wd:Q34369823 wd:Q43188658 wd:Q83930160 wd:Q33384668 wd:Q33391803 wd:Q34603644 wd:Q33386052 wd:Q34753416 wd:Q33942495 wd:Q44010411 wd:Q33386405 wd:Q36478461 wd:Q60976563 wd:Q77929272 wd:Q34549410
p:P2093
wds:Q34008578-E02BD83A-8E0C-4BC0-B98B-6E0F4A5891D2 wds:Q34008578-EA936645-468B-4BBB-A420-1A41BF219459 wds:Q34008578-10AB29C6-81E3-44FB-A7CC-476507A41CB6 wds:Q34008578-2E590EF0-0D22-4F6D-9B60-CB139102246F wds:Q34008578-262154CD-09DF-4A0E-996F-15DF0E81486D wds:Q34008578-6EE6E791-98B0-42B0-AE0A-87F3A14A73EE wds:Q34008578-8A4D593A-8965-4486-9329-3FD6D217FEBA wds:Q34008578-8F8F1541-B2FF-49E2-BFE7-0597ADCFA844 wds:Q34008578-48D612C9-7690-45D4-B70F-98A0BE77B03F wds:Q34008578-4614DE32-8C7D-4FDF-9EFF-2423633EF49F wds:Q34008578-F8D76537-A4B9-4016-A1E1-BC94BCC7EA63
wdt:P2093
Palka Anand Deborah Doss Mohamad H Zaki Min Chen Susan L Kelley Daniel Sullivan David Siegel Nora Loughney Lisa Nardelli Gail Larkins Christian Jacques
rdfs:label
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
skos:prefLabel
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
schema:name
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
p:P50
wds:Q34008578-FDF9A02F-520B-4F32-96D0-C3295DC514E6 wds:Q34008578-D32F5F94-4154-414A-ABB1-603689127147 wds:Q34008578-DBABA3EF-8670-46FE-A435-F905BBE5288F wds:Q34008578-8B6D1B0E-15A9-4341-AEF4-BB7F34EFAA4B wds:Q34008578-8D426718-CB6E-4D9D-BAFE-6B28BB0F6207 wds:Q34008578-6C1B0418-78C4-4A34-8621-75FB05D23AA0 wds:Q34008578-6DBCDD67-F6F1-4F4E-B951-767E4264D05C wds:Q34008578-39725989-2BB3-44FE-BE00-B82C91D0AF73 wds:Q34008578-3CECEA05-5DEF-414F-8B6A-D95082BF7F7A wds:Q34008578-498EB893-4AE6-4956-A1E1-D9BAED192D80 wds:Q34008578-0D4CB231-B689-4C0D-86F2-E9773C71A688
wdt:P50
wd:Q88032966 wd:Q89228014 wd:Q87712102 wd:Q114300414 wd:Q87654493 wd:Q117261653 wd:Q117224757 wd:Q117224758 wd:Q117224729 wd:Q87769541 wd:Q28421846
p:P1476
wds:Q34008578-74CB4AE3-BD84-4072-B2B1-49C2007ECD79
wdt:P1476
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
p:P304
wds:Q34008578-7892848C-76A1-4580-998A-7AE69EF80AD1
wdt:P304
1961-1967
p:P31
wds:Q34008578-7C2F0CC9-DB14-4670-92DB-8ED3FC408B52
wdt:P31
wd:Q13442814
p:P921
wds:Q34008578-38D32ADB-2CAF-4F1B-9BF4-78797E4667E2 wds:Q34008578-45CCEAC7-E052-4B23-BEC4-7778AEF023F5 wds:Q34008578-CCF64525-1352-431C-AF37-F8CE2E24C5C7
wdt:P921
wd:Q7227206 wd:Q181600 wd:Q467635
p:P698
wds:Q34008578-EBB3C7D6-AF2C-4258-8EF6-27E40EBED0F1
wdtn:P698
n12:23243282
wdt:P698
23243282
p:P1433
wds:Q34008578-6B3C06C3-4ED0-4A79-8639-FA78E52E10A6
wdt:P1433
wd:Q885070
p:P433
wds:Q34008578-85872ED1-50CA-4CA0-A350-84FD45C6F053
p:P478
wds:Q34008578-0A6E9F2B-EF23-4B24-8FFB-7396296E194E
wdt:P433
11
wdt:P478
121
p:P356
wds:Q34008578-5E603DD1-8B60-4667-B7C3-00D0A4B0AD99
wdtn:P356
n10:BLOOD-2012-08-450742
wdt:P356
10.1182/BLOOD-2012-08-450742
p:P5875
wds:Q34008578-2A496B37-0728-4B20-875E-1EE0C45FB6AF
wdt:P5875
233931681
p:P932
wds:Q34008578-96BD6966-46BD-47E2-BC8D-376478C22CDE
wdt:P932
4123324